Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

Ineverlose7 Jul. 1 at 10:06 PM

$ACRS realistically looking at Market cap / narrative / what aclaris is capable of achieving, 5-6 billion market cap is very possible. Not much liquidity needed to get there considering. Crypto bros sell some crypto and lets pump this baby!! 😂

0 · Reply

OriginalTradeonrumor Jul. 1 at 5:26 AM

$ACRS great day all —congrats!!!

1 · Reply

OriginalTradeonrumor Jul. 1 at 5:25 AM

$ACRS Vlad is sad 🤪🤣

2 · Reply

OriginalTradeonrumor Jul. 1 at 5:22 AM

$ACRS 🤔

0 · Reply

Acan1219 Jun. 30 at 9:20 PM

$ACRS AH’s🚀🚀🚀🔥🔥🔥

2 · Reply

Banana0815 Jun. 30 at 8:20 PM

$ACRS insane afterhour

0 · Reply

Shisateh1 Jun. 30 at 8:08 PM

$ACRS a beautiful run today! Usually when that happens it drops by much, yet it shows it's potential 🙏🏽 stay long stay happy, I believe good things to come here

0 · Reply

NotBornYesterday Jun. 30 at 5:09 PM

$ACRS Peaking above 200WMA and looking technically good. Anybody got a strong opinion on the pipeline? What’s this worth if data is positive? (i’m long a small position from about 3 yrs ago…take profits and be happy or more juice to squeeze?…clearly risk/reward isn’t as good at $5 as it was at $1)

1 · Reply

Puffyk Jun. 30 at 3:22 PM

$ACRS You can tell the results on the trials are going to be amazing and pharma is circling this for a potential merger. This traded above $30. It is going to make quite a few million

0 · Reply

Acan1219 Jun. 30 at 3:16 PM

$ACRS $5.20 New 52 Week High my Bulls!! Let’s Gooo!!

0 · Reply

Aclaris Therapeutics management to meet with Oppenheimer

Jun 4, 2026, 2:00 PM EDT - 4 weeks ago

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:00 AM EDT - 4 weeks ago

Aclaris Therapeutics Transcript: AGM 2026

2026-06-02T00:35:11.000Z - 4 weeks ago

Aclaris Therapeutics initiated with an Outperform at LifeSci Capital

May 28, 2026, 8:30 AM EDT - 5 weeks ago

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 14, 2026, 12:35 PM EDT - 7 weeks ago

Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 14, 2026, 12:35 PM EDT - 7 weeks ago

Aclaris Therapeutics Slides: FY 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

2026-05-07T15:19:50.000Z - 2 months ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

2026-05-07T13:36:55.000Z - 2 months ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

May 7, 2026, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics Slides: Corporate presentation

May 7, 2026, 6:59 AM EDT - 2 months ago

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

2026-05-05T10:58:43.000Z - 2 months ago

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

2026-05-05T08:30:14.000Z - 2 months ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-05-04T20:40:03.000Z - 2 months ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-04-29T12:21:19.000Z - 2 months ago

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Aclaris Therapeutics Transcript: Study update

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Aclaris Therapeutics Press release: Study update

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Aclaris Therapeutics Slides: Study update

2026-04-28T11:21:27.000Z - 2 months ago

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

Apr 28, 2026, 6:30 AM EDT - 2 months ago

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Apr 27, 2026, 4:45 PM EDT - 2 months ago

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

2026-04-27T15:45:50.000Z - 2 months ago

Aclaris Therapeutics management to meet virtually with Craig-Hallum

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Aclaris Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Aclaris Therapeutics Proxy statement: Proxy filing

2026-04-16T11:01:43.000Z - 2 months ago

Aclaris Therapeutics initiated with an Outperform at Oppenheimer

Apr 14, 2026, 12:00 PM EDT - 2 months ago

Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 8, 2026, 8:30 AM EDT - 3 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Mar 27, 2026, 10:10 AM EDT - 3 months ago

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Mar 20, 2026, 11:00 AM EDT - 3 months ago

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

2026-03-18T11:18:06.000Z - 3 months ago

Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug

Mar 18, 2026, 6:55 AM EDT - 3 months ago

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

2026-03-12T11:46:37.000Z - 4 months ago

Helus Pharma appoints Conwell as Chief People Officer

HELP

Mar 10, 2026, 1:40 PM EDT - 4 months ago

Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Feb 26, 2026, 8:40 AM EST - 4 months ago

Aclaris Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-26T12:39:16.000Z - 4 months ago

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

2026-02-26T12:30:02.000Z - 4 months ago

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

Feb 26, 2026, 7:00 AM EST - 4 months ago

Aclaris Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Aclaris Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 6:58 AM EST - 4 months ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-02-24T12:26:58.000Z - 4 months ago

Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052

Feb 24, 2026, 7:00 AM EST - 4 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Feb 12, 2026, 2:30 PM EST - 5 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-01-30T12:11:21.000Z - 5 months ago

Aclaris Therapeutics initiated with a Buy at Craig-Hallum

2026-01-30T12:10:17.000Z - 5 months ago

Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy

Jan 27, 2026, 6:55 AM EST - 5 months ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Jan 12, 2026, 6:55 AM EST - 6 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Jan 6, 2026, 8:00 AM EST - 6 months ago

Aclaris Therapeutics Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Aclaris Therapeutics Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Aclaris Therapeutics Slides: Study Result

Jan 6, 2026, 6:59 AM EST - 6 months ago

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Dec 19, 2025, 4:01 PM EST - 7 months ago

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Dec 2, 2025, 11:00 AM EST - 7 months ago

Aclaris Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 7 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 9:00 AM EST - 8 months ago

Aclaris Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 8 months ago

Aclaris Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 11:00 AM EST - 8 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 9, 2025, 6:00 PM EST - 8 months ago

Aclaris Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 8 months ago

Aclaris Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Aclaris Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 6:59 AM EST - 8 months ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Aclaris Therapeutics Transcript: R&D Day 2025

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Aclaris Therapeutics Slides: FY 2025

Sep 30, 2025, 7:00 AM EDT - 9 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 9:00 AM EDT - 10 months ago

Aclaris Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 10 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Sep 3, 2025, 1:00 PM EDT - 10 months ago

Aclaris Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 8:00 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 11 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Status Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Press release: Status Update

Jul 29, 2025, 5:00 PM EDT - 1 year ago

Aclaris Therapeutics Slides: Status Update

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 1 year ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 11:30 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Jun 30, 2025, 11:30 AM EDT - 1 year ago

Aclaris Therapeutics Slides: FY 2025

Jun 30, 2025, 9:31 AM EDT - 1 year ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 1 year ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 11, 2025, 1:20 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 10:30 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 9:20 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Earnings release: Q1 2025

May 8, 2025, 6:50 AM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

Feb 12, 2025, 6:50 AM EST - 1 year ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 19, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

Dec 3, 2024, 1:00 PM EST - 1 year ago

Aclaris Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Transcript: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Press release: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Slides: Status Update

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q3 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Earnings release: Q2 2024

Jul 16, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 2 years ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 11, 2024, 11:20 AM EDT - 2 years ago

Aclaris Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 2 years ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Slides: Q1 2024

May 7, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Annual report: Q4 2023

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Earnings release: Q4 2023

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Ineverlose7 Jul. 1 at 10:06 PM

0 · Reply

OriginalTradeonrumor Jul. 1 at 5:26 AM

$ACRS great day all —congrats!!!

1 · Reply

OriginalTradeonrumor Jul. 1 at 5:25 AM

$ACRS Vlad is sad 🤪🤣

2 · Reply

OriginalTradeonrumor Jul. 1 at 5:22 AM

$ACRS 🤔

0 · Reply

Acan1219 Jun. 30 at 9:20 PM

$ACRS AH’s🚀🚀🚀🔥🔥🔥

2 · Reply

Banana0815 Jun. 30 at 8:20 PM

$ACRS insane afterhour

0 · Reply

Shisateh1 Jun. 30 at 8:08 PM

$ACRS a beautiful run today! Usually when that happens it drops by much, yet it shows it's potential 🙏🏽 stay long stay happy, I believe good things to come here

0 · Reply

NotBornYesterday Jun. 30 at 5:09 PM

1 · Reply

Puffyk Jun. 30 at 3:22 PM

$ACRS You can tell the results on the trials are going to be amazing and pharma is circling this for a potential merger. This traded above $30. It is going to make quite a few million

0 · Reply

Acan1219 Jun. 30 at 3:16 PM

$ACRS $5.20 New 52 Week High my Bulls!! Let’s Gooo!!

0 · Reply

thatishowitis Jun. 29 at 7:39 PM

$ACRS im sorry retail but you just brought up all the institutional shares at the premium

1 · Reply

Puffyk Jun. 26 at 4:57 PM

$ACRS Setting up for a hyperbolic move with news

0 · Reply

OriginalTradeonrumor Jun. 26 at 3:58 PM

$PYXS not luck..just seeing 2-3 weeks ago XBI strength building and looking at stocks like $ACRS and PYXS as likely receivers of volume and strength—they were ..I minted money …and now I’m out of this stock—-still have some in ACRS and moved big into $CCLD and $SLDP both of which have nothing to do with XBI but are small caps waiting to to be lit —maybe I’ll get “ lucky” again 🤣 Let’s see what happens!

0 · Reply

Puffyk Jun. 25 at 3:17 PM

$ACRS Aclaris Therapeutics (NASDAQ: ACRS) is advancing a pipeline of immuno-inflammatory therapies. Recent trial data and upcoming catalyst dates highlight:ATI-052 (Anti-TSLP/IL-4R Bispecific Antibody):Full results from the Phase 1a trial were recently presented.A Phase 1b trial in Atopic Dermatitis is underway, with readouts expected in the second half of 2026.A Phase 2 asthma study is slated to begin in the fourth quarter of 2026.ATI-2138 (ITK/JAK3 Inhibitor):Data from the Phase 2a trial was recently presented at the American Academy of Dermatology Annual Meeting.A Phase 2 trial for chronic inflammatory and immune-mediated disorders (including lichen planus) is scheduled to start in the second half of 2026.Bosakitug / ATI-045 (Monoclonal Antibody):Currently in Phase 2 for Atopic Dermatitis.Top-line results are anticipated in the fourth quarter of 2026.

0 · Reply

Puffyk Jun. 23 at 4:05 PM

$ACRS Trial Data to be released in 3Q. This is setting up for $15+ with positive news. The accumulation is showing the hedge funds expect positive news.

1 · Reply

Banana0815 Jun. 23 at 3:24 PM

$ACRS did i miss something?

0 · Reply

OriginalTradeonrumor Jun. 23 at 2:13 PM

$ACRS $CCLD hope everyone stayed in ACRS! In the 5’s now! Huge gains …I’m selling more today for profits …but still holding decent amount as ACRS is a long term play —CCLD is same …flushed down but will be getting back on its feet soon —buying CCLD where it’s at now 2.15 and up 10-20 cents higher is a gift

1 · Reply

doo Jun. 23 at 2:07 PM

$ACRS Lets goooo

0 · Reply

OriginalTradeonrumor Jun. 22 at 2:10 PM

$ACRS XBI screaming…ACRS.screaming right along with it ..congrats all who didn’t get shaken out or put off by people saying it will go to the 3’s 🤣—I’ve taken some profit ( yet again!) but def still in!!!

0 · Reply

Vladxccc Jun. 16 at 12:26 PM

$ACRS 🤹‍♂️

0 · Reply

OriginalTradeonrumor Jun. 16 at 5:43 AM

$ACRS nice shake today……looks like it took some folks out —-gotta ride the bull! $CCLD doing same …small caps do this more so ( exaggerated) than large caps—-it’s a chance to cost avg if you bought higher …or simply just ride it out ——it’s all paper gains / losses until you sell!

0 · Reply

Acan1219 Jun. 15 at 7:55 PM

$ACRS See you my Bull’s! I’m out!

1 · Reply

Market Cap	776.53M
Revenue (ttm)	7.83M
Net Income (ttm)	-64.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-829.12%
Debt to Equity Ratio	0.00

Volume	1,943,000
Avg Vol	1,607,772
Day's Range	N/A - N/A
Shares Out	139.66M
Stochastic %K	89%
Beta	0.76
Analysts	Strong Sell
Price Target	$10.00